All In Biotech

Drug Trial Radar · NCT05243680

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744

Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

641

Actual

Start

Mar 1, 2022

Primary completion

May 19, 2025

Study completion May 19, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Feb 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.

Conditions

  • Asthma

Interventions

  • GSK3511294 (Depemokimab)Biological

    GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs)Time frame: Up to Week 56
  2. Number of Participants With Worst Case Post-Baseline Positive Anti-GSK3511294 Antibodies (ADA)Time frame: Up to Week 52
  3. Number of Participants With Worst Case Post-Baseline Positive Neutralizing AntibodiesTime frame: Up to Week 52

Locations

137 sites in 14 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Lancaster, California

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Lafayette, Colorado

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Loxahatchee Groves, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Savannah, Georgia

  • GSK Investigational Site

    Normal, Illinois

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Ypsilanti, Michigan

  • GSK Investigational Site

    Northfield, New Jersey

  • GSK Investigational Site

    Toms River, New Jersey

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Gastonia, North Carolina

  • GSK Investigational Site

    Huntersville, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    DuBois, Pennsylvania

  • GSK Investigational Site

    Allen, Texas

  • GSK Investigational Site

    Boerne, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Kerrville, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Bellingham, Washington

  • GSK Investigational Site

    Coffs Harbour, New South Wales, Australia

  • GSK Investigational Site

    South Brisbane, Queensland, Australia

  • GSK Investigational Site

    Sherwood Park, Alberta, Canada

  • GSK Investigational Site

    Kamloops, British Columbia, Canada

  • GSK Investigational Site

    Ajax, Ontario, Canada

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Changchun, China

  • GSK Investigational Site

    Changchun, China

  • GSK Investigational Site

    Chengdu, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Guangzhou, China

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.